Welcome to our dedicated page for Henry Schein news (Ticker: HSIC), a resource for investors and traders seeking the latest updates and insights on Henry Schein stock.
Overview of Henry Schein, Inc.
Henry Schein, Inc. (NASDAQ: HSIC) is a global leader in the distribution of healthcare products and services, specializing in serving office-based dental, medical, and animal health practitioners, as well as dental laboratories, government and institutional healthcare facilities, and other alternate care sites. With a robust presence as a Fortune 500 and S&P 500 company, Henry Schein operates in over 33 countries and territories, providing solutions to more than one million customers worldwide.
Core Business and Product Portfolio
The company's core business revolves around its extensive portfolio of over 100,000 in-stock branded and private-label products, complemented by more than 150,000 special-order items. These products cater to a wide range of healthcare needs, from dental supplies and medical equipment to animal health products. Henry Schein also offers innovative technology solutions designed to enhance operational efficiency and improve clinical outcomes. These include practice management software, analytics tools, and other digital solutions tailored to healthcare providers.
Operational Model and Distribution Network
Henry Schein operates a centralized and automated distribution network, a key element of its business model. This network ensures efficient delivery of products and services, enabling healthcare providers to focus on patient care. The company’s value-added services, such as inventory management, equipment repair, and financial planning, further enhance its appeal to healthcare practitioners looking to streamline operations.
Market Position and Competitive Landscape
As a major player in the healthcare distribution industry, Henry Schein competes with other prominent companies like Patterson Companies and McKesson. Its competitive edge lies in its comprehensive product offerings, global reach, and commitment to technology-driven solutions. The company’s focus on innovation and customer-centric services allows it to maintain a strong market position in an increasingly competitive landscape.
Strategic Growth and Acquisitions
Henry Schein has demonstrated a strategic approach to growth through acquisitions. For example, its recent acquisition of Acentus, a supplier specializing in Continuous Glucose Monitors (CGMs), highlights its efforts to expand into specialized medical product categories. Such acquisitions not only diversify its portfolio but also bring in additional expertise and capabilities, reinforcing its leadership in the healthcare sector.
Significance in the Healthcare Industry
Henry Schein plays a critical role in the healthcare supply chain, bridging the gap between manufacturers and healthcare providers. Its ability to offer a wide range of products and services under one roof makes it an indispensable partner for practitioners aiming to deliver high-quality care. By leveraging technology and a customer-focused approach, the company continues to set benchmarks in operational efficiency and clinical support.
Conclusion
Henry Schein, Inc. stands out as a comprehensive solutions provider in the healthcare industry. Its vast product portfolio, innovative technology offerings, and strategic growth initiatives position it as a trusted partner for healthcare practitioners worldwide. With a focus on operational efficiency and clinical excellence, Henry Schein remains a cornerstone in the global healthcare ecosystem.
Henry Schein reported third-quarter 2022 net sales of $3.1 billion, a 3.5% decline from Q3 2021. Internal sales growth, excluding PPE and COVID-19 products, rose 6.8% in local currencies. GAAP diluted EPS for the quarter was $1.09, down from $1.15 year-over-year, while non-GAAP diluted EPS increased to $1.15 from $1.10. The full-year 2022 non-GAAP diluted EPS guidance is narrowed to $4.79 to $4.87, reflecting a potential growth of 6% to 8% compared to 2021. The company expects full-year sales growth of 1.5% to 2.5%.
Henry Schein, trading under NASDAQ: HSIC, announces its participation in two investor conferences in November 2022. The first is Credit Suisse's 31st Annual Healthcare Conference on November 9 at the Terranea Resort, California, followed by Stifel's 2022 Healthcare Conference on November 15 at the Lotte New York Palace, New York City. Both presentations will be available via live webcast on the company's website and replays will be accessible afterward. Henry Schein is a leader in healthcare solutions, serving over 1 million customers globally.
Henry Schein (NASDAQ: HSIC) announced that Steven W. Kess, Vice President of Global Professional Relations, received a Presidential Citation from the American Dental Association (ADA) during SmileCon 2022 in Houston, Texas, on October 13. This recognition honors significant contributions to public oral health, particularly through the Give Kids A Smile program, which has served over seven million children since 2003. Kess emphasized ongoing efforts to enhance access to oral care for underserved communities.
Smile Brands has selected Dentrix Ascend as its exclusive cloud-based practice management system for its 700 dental locations. The decision followed a year-long market analysis and pilot program, confirming Dentrix Ascend's superior clinical features and integration capabilities. This software will enhance operational efficiency by allowing remote access to data and reducing management burdens. CEO Steve Bilt emphasized that this partnership aligns with their vision of improving patient experiences. Henry Schein One, the software provider, supports this initiative aiming for enhanced quality of care.
Henry Schein, Inc. announces a donation of up to
Henry Schein (Nasdaq: HSIC) has been recognized in FORTUNE® magazine's "Change the World" list for its initiatives to advance health equity for individuals with disabilities. This marks the third acknowledgment for the company, highlighting its commitment to addressing care gaps for 61 million people in the U.S. living with disabilities. Key efforts include public-private partnerships, educating healthcare professionals, and designing accessible dental products. The company emphasizes that strong financial performance aligns with its mission for societal impact.
Henry Schein, Inc. (Nasdaq: HSIC), the largest provider of health care solutions for dental and medical practitioners, will release its Q3 2022 financial results on November 1, 2022. The earnings conference call starts at 10:00 a.m. Eastern time on the same day, featuring CEO Stanley M. Bergman and CFO Ronald N. South. Investors can access the live webcast on the company’s website. Henry Schein reported $12.4 billion in sales for 2021 and operates in 32 countries with a strong distribution network.
Henry Schein (Nasdaq: HSIC) has launched its 16th annual Practice Pink program, raising over
BD (Becton, Dickinson and Company) has announced a grant of $360,000 to six U.S. free clinics as part of its Point-of-Care, Enhancing Clinical Effectiveness initiative. This program, established in 2017, has supported 27 clinics across 20 states with a total of $2.6 million. The initiative aims to improve health outcomes in underserved communities by providing diagnostic testing capabilities for common health issues, impacting over 16,500 patient visits this year. Collaborating partners include Heart to Heart International and the National Association of Free and Charitable Clinics.
FAQ
What is the current stock price of Henry Schein (HSIC)?
What is the market cap of Henry Schein (HSIC)?
What does Henry Schein, Inc. specialize in?
How does Henry Schein generate revenue?
What is unique about Henry Schein's business model?
Who are Henry Schein's main competitors?
What recent acquisitions has Henry Schein made?
What role does technology play in Henry Schein's operations?
What industries does Henry Schein serve?
How does Henry Schein differentiate itself in the market?
